Synergy CHC (SNYR) Stock Price

Synergy CHC Price

NYSE·CLOSED
0.01
​
Market closed

Over the last 11 years Synergy CHC grew revenue by 109.0% annually, reaching 30.38 M USD. Earnings per share have grown at 75.0% per year over the last 7 years. For Synergy CHC, the net margin of -40.6% is down versus 3.5% a few years ago.

Synergy CHC stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synergy CHC business model & stock analysis

Synergy CHC Corp., a consumer health care company, markets and distributes various consumer branded products primarily in the health and wellness industry in North America. The company is headquartered in Westbrook, Maine and currently employs 36 full-time employees. The company went IPO on 2013-11-08. The firm is engaged in the process of building a portfolio of consumer product brands. The firm is involved in the business of marketing and distributing consumer branded products through various distribution channels primarily in the health and wellness industry. The firm's portfolio of brands includes FOCUSfactor, Neuragen, Hand MD, UrgentRx and Flat Tummy Tea. FOCUSfactor is a brain health nutritional supplement that includes a blend of brain supporting vitamins, minerals, antioxidants and other nutrients. Flat Tummy Tea is a formulated two-step herbal detox tea that works to naturally help speed metabolism, boost energy and reduce bloating. Neuragen is a topical product that works directly at the site of the pain as opposed to oral products. UrgentRx provides relief for a range of every day ailments, such as allergy attacks, headaches, aches and pains, heartburn and upset stomach.

Frequently asked questions about Synergy CHC

7 analysts currently rate the Synergy CHC stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Synergy CHC to generate revenue of 31.50 M USD and earnings per share of -0.13 USD.

Converted at the current exchange rate, the Synergy CHC share trades at 0.01 EUR (0.01 USD).

The expected revenue of Synergy CHC is 31.50 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Synergy CHC is -1.45 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Synergy CHC is currently -0.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Synergy CHC stock.

The price-to-sales ratio (P/S) of Synergy CHC is currently 0.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Synergy CHC stock.

The Eulerpool Quality Score for Synergy CHC is 3/10.

The ISIN of Synergy CHC is US87165D2080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Synergy CHC is SNYR. The ticker symbol is used to trade Synergy CHC shares on the stock exchange.

Fair ValueTerminal
0.01 USD
Over-/UndervaluationTerminal
Fairly valued
Industry
Personal Products
Number of shares
Employees
Revenue per Employee
1.09 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 8, 2013
ISIN
US87165D2080
Cusip
87165D109
Sedol
BLZHDF8
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.11
P/Ee 2027
0.10
P/S
P/Se
0.01
EV/EBIT
—
P/B Ratio
0.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-334.77 %
Last updated Nov 11, 2026, 8:17 PM

All fundamentals and in-depth analysis of Synergy CHC

Our stock analysis for Synergy CHC stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Synergy CHC. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.